Education
About Us
Working with TipRanks
Follow Us
Epigenomics (DE:ECX)
FRANKFURT:ECX
ECX Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.50 - €2.30
Previous CloseN/A
Volume5.06K
Average Volume (3M)1.27K
Market Cap
€806.79K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)966.00K
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Aug 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.92
Shares Outstanding876,949
10 Day Avg. Volume474
30 Day Avg. Volume1,266
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ECX FAQ
What was Epigenomics’s price range in the past 12 months?
Epigenomics lowest stock price was €0.50 and its highest was €2.30 in the past 12 months.
What is Epigenomics’s market cap?
Epigenomics’s market cap is €806.79K.
When is Epigenomics’s upcoming earnings report date?
Epigenomics’s upcoming earnings report date is Aug 06, 2025 which is in 8 days.
How were Epigenomics’s earnings last quarter?
Epigenomics released its earnings results on May 07, 2025. The company reported -€2.915 earnings per share for the quarter, missing the consensus estimate of N/A by -€2.915.
Is Epigenomics overvalued?
According to Wall Street analysts Epigenomics’s price is currently Overvalued.
Does Epigenomics pay dividends?
Epigenomics does not currently pay dividends.
What is Epigenomics’s EPS estimate?
Epigenomics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epigenomics have?
Epigenomics has 876,949 shares outstanding.
What happened to Epigenomics’s price movement after its last earnings report?
Epigenomics reported an EPS of -€2.915 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Epigenomics?
Currently, no hedge funds are holding shares in DE:ECX
Epigenomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
-1.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-78.37%
Trailing 12-Months
Company Description
Epigenomics
Epigenomics AG is a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, North America, Asia, and the Rest of the world.
Technical Analysis
B.R.A.I.N. Biotechnology Research and Information Network
―
Heidelberg Pharma AG
―
Bio-Gate AG
―
Vitruvia Medical AG
―
SYNLAB AG
―